Antibacterial agents in infections of the central nervous system

M H Chowdhury1, A R Tunkel

  • 1Department of Medicine, Medical College of Pennsylvania, Hahnemann University, School of Medicine, Philadelphia, USA.

Insights

Experimental animal models guide antimicrobial therapy for central nervous system infections, including bacterial meningitis. New strategies are being tested in clinical trials to combat resistant pathogens.

Area of Science:

  • * Neuroscience
  • * Infectious Diseases
  • * Pharmacology

Background:

  • * Experimental animal models are crucial for understanding antimicrobial therapy in central nervous system (CNS) infections.
  • * Bacterial meningitis treatment efficacy relies on drug penetration of the blood-brain barrier, activity in cerebrospinal fluid (CSF), and rapid bactericidal action.
  • * The rise of antimicrobial resistance poses a significant challenge to treating bacterial meningitis.

Purpose of the Study:

  • * To review the role of experimental animal models in evaluating antimicrobial therapies for CNS infections.
  • * To discuss strategies for overcoming antimicrobial resistance in bacterial meningitis.
  • * To highlight the translation of promising preclinical findings into clinical trials.

Main Methods:

  • * Review of existing literature on experimental animal models for CNS infections.
  • * Analysis of factors influencing antimicrobial efficacy in bacterial meningitis.
  • * Examination of novel therapeutic strategies against resistant pathogens.

Main Results:

  • * Animal models have yielded valuable insights into antimicrobial drug properties essential for CNS penetration and efficacy.
  • * Various treatment strategies targeting resistant bacterial meningitis have shown promise in preclinical studies.
  • * Encouraging results from animal models have prompted clinical investigations of new antimicrobial agents.

Conclusions:

  • * Experimental animal models remain indispensable for advancing antimicrobial therapy for CNS infections.
  • * Addressing antimicrobial resistance in bacterial meningitis requires innovative therapeutic approaches.
  • * Clinical trials informed by preclinical research are vital for validating new treatment regimens.

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Brain Abscess l: Introduction01:26

Brain Abscess l: Introduction

A brain abscess is a focal, intracerebral infection characterized by a localized collection of pus within the brain parenchyma, resulting from microbial invasion and the body’s inflammatory response. It progresses through stages: early and late cerebritis, followed by early and late capsule formation, reflecting tissue destruction, immune response, and eventual encapsulation.Etiology and PathogenesisCausative organisms vary with source and host factors, often involving polymicrobial infections,...